ASNDAscendis Pharma A/S
What is the market doing?
No clear lean: rangebound and insiders net selling (often routine).
Rangebound, no clear trend. Price is −1% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Moderately shorted, settled Sep 15, 2026, about a week of normal trading to cover. Down 5.7% since the previous count, up from 3.3% of shares outstanding three months ago.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How ASND is trading
Ascendis Pharma A/S is +16% over the past year while the S&P 500 is +18%: 2.4 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −1.4%
vs 200-day average · below trend, but not far
- RSI (14)
- 42
RSI (14) · neutral
- Below its 52-week high
- 16%
Below its 52-week high
Details›
- Last close2026-10-09
- $229.11
- 1 monthS&P 500 +2.7%
- −12%
- 1 yearS&P 500 +18%
- +16%
- 5 yearsS&P 500 +88%
- +49%
- vs 50-day average$246.39
- −7.0%
- 52-week high
- $271.13
- 52-week low
- $189.74
- Annualised volatility
- 40%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$4.7M
| Year | Return |
|---|---|
| 2026 (year to date) | +7.4% |
| 2025 | +55% |
| 2024 | +9.3% |
| 2023 | +3.1% |
| 2022 | −9.2% |
| 2021 | −19% |
| 2020 | +20% |
| 2019 | +122% |
| 2018 | +56% |
| 2017 | +98% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 6 of 10 | +3.0% |
| Feb | 10 | 7 of 10 | +8.0% |
| Mar | 10 | 4 of 10 | +3.2% |
| Apr | 10 | 5 of 10 | −2.6% |
| May | 10 | 4 of 10 | +1.5% |
| Jun | 10 | 7 of 10 | +3.7% |
| Jul | 11 | 6 of 11 | −1.4% |
| Aug | 11 | 9 of 11 | +9.2% |
| Sep | 11 | 7 of 11 | +3.4% |
| Oct | 11 | 5 of 11 | −1.1% |
| Nov | 10 | 9 of 10 | +5.3% |
| Dec | 10 | 5 of 10 | +4.3% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.